amlodipine--atorvastatin-drug-combination and Metabolic-Syndrome

To examine whether addition of amlodipine (5 mg)/atorvastatin (10 mg) A/A to Therapeutic Lifestyle change intervention (TLC) would beneficially modulate Metabolic Syndrome (MetS) and oxidized low-density lipoprotein (Ox-LDL) levels.. Patients with MetS (n = 53) were randomized to TLC + placebo or TLC + A/A for 12 months. Anthropometric measurements, blood pressure (BP), lipid profile, plasma Ox-LDL, and area under the curve of free fatty acid (AUC. 1) Addition of A/A has the advantage of improving the lipid profile and BP; but TLC alone was comparable to TLC + A/A in improving MetS; 2) weight change determines the TLC-associated change in Ox-LDL levels; and 3) AT metabolic health is a significant predictor of TLC-associated loss of body fat mass.

Topics: Adult; Aged; Amlodipine; Atorvastatin; Behavior Therapy; Biomarkers; Blood Pressure; Cardiometabolic Risk Factors; Combined Modality Therapy; Drug Combinations; Female; Heptanoic Acids; Humans; Life Style; Lipids; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Placebos; Pyrroles; Risk Reduction Behavior